Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement

Copenhagen, Denmark; September 29, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons.

The sale of shares by Jan van de Winkel is primarily to honor tax obligation arising out of his participation in Genmab A/S' equity program in the income years 2017, 2018 and 2019. The sale of shares will take Jan van de Winkel's personal holding of shares in Genmab A/S from 671,423 to 641,423 shares.

Please find below a statement of such trading in shares issued by Genmab A/S

1.	**Details of the person discharging managerial responsibilities / person closely associated**		
a)	Name	Jan van de Winkel	
2.	**Reason for the notification**		
a)	Position/status	President & Chief Executive Officer	
b)	Initial notification/Amendment	Initial notification	
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**		
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**		
a)	Description of the financial instrument, type of instrument Identification code	Share DK0010272202	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 2,344	20
		DKK 2,345	181
		DKK 2,346	98
		DKK 2,347	280
		DKK 2,348	166
		DKK 2,349	140

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

		DKK 2,350	154
		DKK 2,351	210
		DKK 2,352	60
		DKK 2,353	42
		DKK 2,354	2,267
		DKK 2,354.50	6
		DKK 2,355	27
		DKK 2,356	66
		DKK 2,357	108
		DKK 2,358	228
		DKK 2,358.50	40
		DKK 2,359	46
		DKK 2,359.50	40
		DKK 2,360	159
		DKK 2,360.50	80
		DKK 2,361	478
		DKK 2,361.50	383
		DKK 2,362	429
		DKK 2,362.50	43
		DKK 2,363	602
		DKK 2,363.50	43
		DKK 2,364	528
		DKK 2,364.50	122
		DKK 2,365	389
		DKK 2,366	383
		DKK 2,366.50	43
		DKK 2,367	185
		DKK 2,367.50	107
		DKK 2,368	238
		DKK 2,368.50	83
		DKK 2,369	217
		DKK 2,369.50	137
		DKK 2,370	2,888
		DKK 2,370.50	92
		DKK 2,371	681
		DKK 2,371.50	64
		DKK 2,372	181
		DKK 2,373	194

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

		DKK 2,373.50	254
		DKK 2,374	255
		DKK 2,374.50	163
		DKK 2,375	437
		DKK 2,375.50	317
		DKK 2,376	255
		DKK 2,376.50	271
		DKK 2,377	189
		DKK 2,377.50	598
		DKK 2,378	490
		DKK 2,378.50	384
		DKK 2,379	267
		DKK 2,379.50	206
		DKK 2,380	687
		DKK 2,380.50	869
		DKK 2,381	777
		DKK 2,381.50	465
		DKK 2,382	1,452
		DKK 2,382.50	249
		DKK 2,383	461
		DKK 2,383.50	105
		DKK 2,384	1,486
		DKK 2,384.50	644
		DKK 2,385	1,277
		DKK 2,385.50	532
		DKK 2,386	2,086
		DKK 2,386.50	286
		DKK 2,387	677
		DKK 2,387.50	60
		DKK 2,388	603
		DKK 2,388.50	109
		DKK 2,389	63
		DKK 2,393	98
d)	Aggregated information - Aggregated volume - Price	30,000 DKK 2,373.72	
e)	Date of the transaction	2020-09-29	
f)	Place of the transaction	CBOE Europe (BATD, BATE, BATP, CHID and CHIX) Goldman Sachs International (GSSI)	

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

		Nasdaq Copenhagen (DCSE, MCSE and XCSE) Sigma (SGMX and SGMY) Turquoise (TRQM and TRQX)

1.	**Details of the person discharging managerial responsibilities/person closely associated**	
a)	Name	Anders Gersel Pedersen
2.	**Reason for the notification**	
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	Genmab A/S
b)	LEI	529900MTJPDPE4MHJ122
4.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument Identification code	Share DK0010272202
b)	Nature of the transaction	Subscription of shares (exercise of warrants)
c)	Price(s) and volume(s)	**Price(s)** / **Volume(s)** DKK 40.41 / 7,500
d)	Aggregated information - Aggregated volume - Price	
e)	Date of the transaction	2020-09-29
f)	Place of the transaction	Outside a market place

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX® (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta® (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA® (teprotumumab, under agreement with Roche granting sublicense to Horizon

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra® (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact:
Marisol Peron, Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.